Staying up-to-date has never been simpler. Sign up for the free GenePool newsletter today!
Lyon, France, June 10, 2013 - Imaxio, a biopharmaceutical company specialized in vaccines and genomics, announces today that it has signed a license option agreement with a major animal health laboratory, a top ten company globally in its sector. The aim of the agreement is to develop a number of veterinary vaccines using Imaxio’s immuno-enhancing IMX313 technology.
The agreement grants the partner permission to carry out its own evaluation of Imaxio’s IMX313 technology. Subject to the results of the evaluation it provides the option of a license agreement to use IMX313 in developing vaccines for a total of four animal health indications. The name of the partner and the technical and financial terms of the agreement are not disclosed.
Imaxio’s proprietary antigen re-engineering technology, IMX313, is designed to enhance the immune response and, therefore, the effectiveness of vaccines with which it is combined. IMX313 offers significant potential as a solution to developing vaccines for major indications in response to the challenge posed by some human and animal health candidates which lack effectiveness.
“This new agreement with a major player in veterinary pharmacy is a further boost to our confidence in the IMX313 technology, following Imaxio signing the license option with Merial last December. The IMX313 technology is crucial to our continued in-house development of vaccines for tuberculosis, flu, staphylococcus aureus and veterinary cryptosporidiosis,” said Alexandre Le Vert, chief executive officer of Imaxio. “We are delighted to have secured promising collaboration agreements with renowned academic and industrial partners. This enables us to promote the use of IMX313 in the development of vaccines and immunotherapies for use in additional indications. We are keen to build on our initial success and are therefore continuing to seek out potential partners.”
About Imaxio SA
Imaxio SA is a biopharmaceutical company specialized in the areas of vaccines and genomics.
Using IMX313, its antigen re-engineering technology, Imaxio is developing, both individually and with its partners, recombinant vaccines with improved effectiveness for applications in both human and animal health. In France, Imaxio already markets Spirolept(R), a human vaccine indicated for preventing a professional infectious disease, and Trolovol(R), an orphan drug indicated for a congenital metabolic disease.
Imaxio’s genomics division undertakes diagnostic and therapeutic research in the field of oncology and immunology, as well as providing services in the areas of human health, the agro-food business and the environment.
Imaxio was created through the merger between Diagnogene and Avidis, a spin-off from the Medical Research Council and Cambridge University in the UK. The company owns well-founded intellectual property and collaborates with numerous academic partners, including the Jenner Institute at Oxford University.
Imaxio SA is based in Lyon and at Saint Beauzire, near Clermont-Ferrand in France. It has 24 employees, twelve of whom are engaged in R&D. In 2012 it delivered a turnover of EUR 2.7 million.
For more information, go to: http://www.imaxio.com and http://www.genomics-imaxio.com
Mark Tidmarsh
ANDREW LLOYD & ASSOCIATES
http://www.ala.commark@ala.com
Follow us on Twitter: https://twitter.com/ALA_Group
Brighton Business Centre 95 Ditchling Road Brighton BN1 4ST ENGLAND
Tel: +44 1273 675100 Fax: +44 1273 675400
55 rue Boissonade 75014 Paris FRANCE
Tel: +33 1 56 54 07 00 Fax: +33 1 56 54 07 01
INTERNATIONAL TECHNOLOGY MARKETS, STRATEGY & COMMUNICATION
Help employers find you! Check out all the jobs and post your resume.
